ETF profile for Yieldmax Mrna Option Income Strategy ETF (MRNY) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
MRNY ETF Profile
| Family: |
Elevate Shares |
| Name: |
YieldMax MRNA Option Income Strategy ETF |
|
|
| Inception Date: |
23-Oct-2023 |
| Termination Date: |
|
| Investment Objective: |
The Fund's primary investment objective is to seek current income. The Fund's secondary investment objective is to seek exposure to the share price of the common stock of Moderna, Inc. ("MRNA" or "Underlying Security"), subject to a limit on potential investment gains. The Fund is an actively managed exchange-traded fund ("ETF") that seeks current income while providing indirect exposure to the share price (i.e., the price returns) of the common stock of Moderna, Inc. ("MRNA" or the "Underlying Security"), subject to a limit on potential investment gains. The Fund will employ its investment strategy as it relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will take temporary defensive positions during such periods. As further described below, the Fund uses either a synthetic covered call strategy or a synthetic covered call spread strategy to provide income and indirect exposure to the share price returns of MRNA, subject to a limit on potential investment gains as a result of the nature of the options strategy it employs. That is, the Fund not only seeks to generate income from its options investments but also aims to derive gains when the value of MRNA increases. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| MRNA 11/20/2026 135.01 C |
|
46.6300% |
| United States Treasury Bill 07/08/2027 |
B 0 07/08/27 |
18.9100% |
| United States Treasury Bill 02/18/2027 |
B 0 02/18/27 |
12.0000% |
| United States Treasury Note/Bond 3.375% 09/15/2027 |
91282CLL3 |
11.7500% |
| United States Treasury Note/Bond 2.375% 05/15/2027 |
912828X88 |
10.2500% |
| MRNA US 10/23/26 C222.5 |
|
-4.3600% |
| United States Treasury Bill 12/10/2026 |
B 0 12/10/26 |
3.6700% |
| MRNA US 10/23/26 C235 |
|
2.5400% |
| MRNA US 10/23/26 C240 |
|
-1.3000% |
| MRNA US 10/23/26 C252.5 |
|
0.7500% |
|
Top 10 Holdings Weight: |
100.8% |
| Number of Holdings: |
18 |
| Shares Outstanding: |
5,979,974 |
| Total Net Assets: |
275,557,216 |
| NAV: |
45.93 |
| Net Expense Ratio: |
1.00% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
US |
| Region: |
|
| Strategy: |
Covered Call Strategy |
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Pharmaceuticals |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Large Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Domestic |
